Literature DB >> 31238363

Stem Cells for Extreme Prematurity.

Bernard Thébaud1,2,3,4.   

Abstract

Regenerative medicine is a bourgeoning field promising to repair damaged organs and thus has created high hopes in neonatology to curb some of the complications due to extreme preterm birth. Extensive laboratory investigations over the past 15 years have tried to harness the regenerative potential of a variety of (stem) cell-based therapies. Most preclinical studies have focused on experimental neonatal lung and brain injury. These promising results lead to the initiation of phase I clinical trials for chronic lung disease of prematurity and severe intraventricular hemorrhage, two of the most devastating complications of extreme preterm birth. Despite this relative rapid clinical translation, major gaps persist in our understanding of the biology of these putative repair cells and our ability to predict the quality and thus the efficacy of the cell product. This review will provide a brief overview of the various cell-based therapies that have been investigated in experimental neonatal lung injury and the remaining challenges in utilizing these new, disruptive therapies to their full extend to realize the promise of regenerative medicine in neonatology. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2019        PMID: 31238363     DOI: 10.1055/s-0039-1691774

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  2 in total

1.  A protocol for cell therapy infusion in neonates.

Authors:  Elizabeth K Baker; Euan M Wallace; Peter G Davis; Atul Malhotra; Susan E Jacobs; Stuart B Hooper; Rebecca Lim
Journal:  Stem Cells Transl Med       Date:  2021-01-06       Impact factor: 6.940

2.  Stem Cells as Therapy for Necrotizing Enterocolitis: A Systematic Review and Meta-Analysis of Preclinical Studies.

Authors:  Eduardo Villamor-Martinez; Tamara Hundscheid; Boris W Kramer; Carlijn R Hooijmans; Eduardo Villamor
Journal:  Front Pediatr       Date:  2020-12-09       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.